UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 29, 2014
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Nevada |
000-555016 |
26-0690857 |
(State or other jurisdiction of
incorporation or organization) |
(Commission File Number) |
(IRS Employer
Identification No.) |
c/o Janssen Labs @QB3
953 Indiana Street
San Francisco, CA |
94107 |
(Address of Principal Executive Offices) |
(Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective August 29,
2014, Iain Ross was appointed as a director and Chairman of the Audit Committee of the Board of Directors of Amarantus Bioscience
Holdings, Inc. (the “Company”).
Following a career with multi-national companies
including Sandoz, Fisons plc and Hoffman La Roche, Mr Ross joined the Board of Celltech Group plc in 1991 and was responsible for
building Celltech Biologics, the contract manufacturing division which was later sold to Alusuisse Lonza. For the last 18 years
he has undertaken a number of start-ups and development stage companies as a board member on behalf of private equity groups and
banks, including Quadrant Healthcare plc, Allergy Therapeutics Ltd, Eden Biodesign Ltd, Phadia AB and Silence Therapeutics plc.
Currently Mr. Ross is Chairman of the Board
of Ark Therapeutics Group PLC and Biomer Technology Ltd, and is also a Non-Executive Director of Benitec Biopharma Limited , Novogen
Limited and Tissue Therapies Ltd each of which is traded on the Australian Securities Exchange. He is a Qualified Chartered Director
of the UK Institute of Directors and Vice Chairman of the Council of Royal Holloway, University of London.
Mr. Ross has no family relationship with
any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Ross
and any other person pursuant to which he was appointed as a director of the Company.
A copy of the Company’s press release
announcing Mr. Ross’s appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release dated August 29, 2014. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
AMARANTUS BIOSCIENCE HOLDINGS, INC. |
|
|
|
|
|
|
|
|
|
|
|
|
Date: August 29, 2014 |
|
By: |
/s/
Gerald E. Commissiong |
|
|
|
|
|
Name: Gerald E. Commissiong |
|
|
|
|
|
Title: Chief Executive Officer |
|
Exhibit 99.1
Amarantus Appoints Iain Ross to Board
of Directors
San Francisco, CA and Geneva, SWITZERLAND – August
29, 2014 - Amarantus Bioscience Holdings, Inc. (OTCQB:
AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic
reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced the appointment of Mr. Iain Ross
to the Company’s Board of Directors, Mr. Ross brings over 30 years of biopharmaceutical industry experience to Amarantus
across executive management, investment and directorship roles.
“Amarantus is poised to become a leading company on the
cutting edge of neurodegenerative disease diagnostic and drug development,” said Iain Ross, a newly-appointed member of the
Amarantus Board of Directors. “The Company has made several key strategic decisions in the last 2 years that have led to
significant appreciation in shareholder value and scientific creditability. As the Company continues on this trajectory, I believe
I will be able to bring significant experience and expertise in strategic planning and execution that will pave the way for continued
shareholder value creation. I am extremely pleased to be joining Amarantus as it works toward listing its common shares on a national
stock exchange in the United States.”
Following a career with multi-national companies including Sandoz,
Fisons plc and Hoffman La Roche, Mr Ross joined the Board of Celltech Group plc in 1991 and was responsible for building Celltech
Biologics, the contract manufacturing division which was later sold to Alusuisse Lonza. For the last 18 years he has undertaken
a number of start-ups and development stage companies as a board member on behalf of private equity groups and banks, including
Quadrant Healthcare plc, Allergy Therapeutics Ltd, Eden Biodesign Ltd, Phadia AB and Silence Therapeutics plc.
Currently he is Chairman of the Board of Ark Therapeutics Group
PLC and Biomer Technology Ltd, and is also a Non-Executive Director of Benitec Biopharma Limited , Novogen Limited and Tissue Therapies
Ltd each of which is traded on the Australian Securities Exchange. He is a Qualified Chartered Director of the UK Institute of
Directors and Vice Chairman of the Council of Royal Holloway, University of London.
“Mr. Ross has an extensive background in biologic drug
development, and strategic corporate transactions that have led to significant accretion of shareholder value,” said Gerald
E. Commissiong, President & CEO of Amarantus. “As we continue on our path to build a world class company, we believe
adding Iain’s leadership to our Board, along with his extensive network in Europe and Australia, will bolster our position
as a leading emerging growth company and broaden our transactional purview.”
About Amarantus BioScience Holdings, Inc.
Amarantus is a biotechnology company developing treatments
and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed
Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license
to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights
to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based
products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT),
a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development
for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease
("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit
www.Amarantus.com, or connect with the Company on Facebook,
LinkedIn, Twitter and Google+.
CONTACTS
Amarantus Bioscience Holdings, Inc.:
Robert Farrell
Chief Financial Officer
408.737.2734 x 102
and
Aimee Boutcher
Investor Relations
408.737.2734 x 101
ir@amarantus.com
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements.” These forward-looking statements generally
are identified by the words believes,” project,” expects,” anticipates,” estimates,” intends,”
strategy,” plan,” may,” will,” would,” will be,” will continue,” will likely result,”
and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks
and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict
results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse
effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not
be placed on such statements.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024